TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05138614

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MISSION Peer Support
Description: including 11 recovery-oriented sessions from someone with lived experience of co-occurring disorders

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MISSION Dual Recovery Therapy
Description: comprised of 13 structured co-occurring disorders treatment sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MISSION Dual Recovery Therapy
Description: comprised of 13 structured co-occurring disorders treatment sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MISSION Dual Recovery Therapy
Description: comprised of 13 structured co-occurring disorders treatment sessions
Study: NCT06235125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytalux
Description: Folate analog ligand conjugated with an indole cyanine-like green dye as a solution in vials containing 3 mL at 2 mg/mL
Study: NCT06374407

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary intervention based on the MIND diet
Description: A 12-week pilot randomized controlled trial (RCT) involving N=126 obese participants (1:1 gender ratio) to assess protocol feasibility, including recruitment, retention, compliance, physical examinations, and gut sample collection. Sample size, calculated by a statistician, expects a 5% body weight change at follow-up (std. dev. 10%). We chose a 12-week duration for this pilot study to allow sufficient time to observe significant changes in both body weight and mental health.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary intervention based on the MIND diet
Description: A 12-week pilot randomized controlled trial (RCT) involving N=126 obese participants (1:1 gender ratio) to assess protocol feasibility, including recruitment, retention, compliance, physical examinations, and gut sample collection. Sample size, calculated by a statistician, expects a 5% body weight change at follow-up (std. dev. 10%). We chose a 12-week duration for this pilot study to allow sufficient time to observe significant changes in both body weight and mental health.
Study: NCT05530239

Intervention type: OTHER
Intervention: Blood sample collection
Description: Blood sample collection

Intervention type: OTHER
Intervention: Blood sample collection
Description: Blood sample collection

Intervention type: OTHER
Intervention: Blood sample collection
Description: Blood sample collection
Study: NCT05576688

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance
Description: Balance was evaluated with Berg Balance Scale (BBS), Functional Reach Test (FRT), One Leg Stance Test (OLST) and Five-Repeat Sit-and-Stand Test (5STS). BBS consists of 14 functional tasks of increasing difficulty, each scored on a scale ranging from 0 to 4. The maximum possible score is 56, indicating no identifiable balance difficulties. FRT measures the maximum distance that participants can reach forward with their dominant arm raised to 90 degrees without moving their feet, which were positioned 10 cm apart. OLST measures the time one is able to stand on one lower limb without support. The test was repeated for both sides. 5STS assesses the time it takes to get up and sit from the chair five times. Measurements were repeated 3 times and the average duration was calculated as a patient score.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trunk control
Description: Trunk control was evaluated with Trunk Impairment Scale (TIS).TIS evaluates static sitting balance, dynamic sitting balance, and trunk coordination on a scale from 0 to 23 points, a higher score indicating a better performance.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait
Description: Gait was evaluated with Dynamic Gait Index (DGI). DGI has 8 items: walking, walking while changing speed, walking while turning the head horizontally and vertically, walking with pivot turn, walking over and around obstacles, and stair climbing. The scoring of the DGI is based on a 4-point scale ranging from 0 to 3, with 0 indicating severe impairment and 3 indicating normal ability. The best performance total score is 24. A low composite DGI score indicates greater impairment in gait.
Study: NCT05138900

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT for central non small cell lung cancer
Study: NCT05576688

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional mobility
Description: Functional mobility was evaluated with Timed Up and Go Test (TUG). TUG is a test of the time required for an individual to stand up from a chair with armrests, walk 3 m, turn, walk back to the chair, and sit down. The stopwatch timing started when the participant's bottom left the chair and ended when the bottom made contact with the chair after the walk.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fear of falling
Description: Fear of falling was evaluated with the Falls Efficacy Scale-International (FES-I). FES-I was used to assess the level of concern about falls during 16 activities of daily living, ranging from basic to more demanding activities including social activities that may contribute to quality of life. It was administered as a self-report questionnaire.
Study: NCT05889858

Intervention type: OTHER
Intervention: Data collection
Description: Data collection
Study: NCT06540222

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sustained cord (≥ 180 seconds) resuscitation
Description: Resuscitation performed in near proximity to the mother with umbilical cord uncut

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Routine (< 60 seconds) cord clamping
Description: Resuscitation performed at a designated area after umbilical cord is cut
Study: NCT05204134

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated Insulin Delivery Settings Initialization and Adaptation Algorithm
Description: All participants wearing the t:slim X2 insulin pump with Control-IQ technology, and wearing the Dexcom G6 sensor, will have algorithm derived insulin delivery profile settings initialization and updates at regular intervals.
Study: NCT06391307

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Crystallized phenol
Description: Crystallized phenol + Exosome + Stem Cell

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Crystallized phenol + Exosome
Description: Crystallized phenol + Exosome will be applied to wound area.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Crystallized phenol + Stem Cell
Description: Crystallized phenol + Stem cell will be applied to wound area.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Crystallized phenol + Exosome + Stem Cell
Description: Crystallized phenol + Exosome + Stem Cell will be applied to wound area.
Study: NCT04678518

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Inflammatory makers that will include Interleukins (IL); IL1, IL2, IL6 and TNF
Description: 1 hour before decannulation and 3 times after decannulation (1 hours, 12 hours and 24 hours)

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Inflammatory makers that will include Interleukins (IL); IL1, IL2, IL6 and TNF
Description: 1 hour before decannulation and 3 times after decannulation (1 hours, 12 hours and 24 hours)
Study: NCT05382273

Intervention type: BEHAVIORAL
Intervention: T-Break Guide
Description: The T-Break Guide was designed to help people complete a 21-day break from cannabis. For each day of the break, the Guide offers inspiration in the form of a quote, reflections based on likely experiences occurring at that point during the break, advice on ways to overcome challenges, alternative activities in which to engage, and encouragement.~* The first week focuses on physical symptoms of cannabis withdrawal (e.g., sleep, appetite).~* The second week focuses on the emotional experience (e.g., anxiety, boredom).~* The third week focuses on behavioral aspects (e.g., examining patterns, connections).~The T-Break Guide follows the Motivational Interviewing principles of affirmation and autonomy.

Intervention type: BEHAVIORAL
Intervention: T-Break Guide
Description: The T-Break Guide was designed to help people complete a 21-day break from cannabis. For each day of the break, the Guide offers inspiration in the form of a quote, reflections based on likely experiences occurring at that point during the break, advice on ways to overcome challenges, alternative activities in which to engage, and encouragement.~* The first week focuses on physical symptoms of cannabis withdrawal (e.g., sleep, appetite).~* The second week focuses on the emotional experience (e.g., anxiety, boredom).~* The third week focuses on behavioral aspects (e.g., examining patterns, connections).~The T-Break Guide follows the Motivational Interviewing principles of affirmation and autonomy.
Study: NCT04647084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% Injectable Solution
Description: An elastic band will be placed around the subject's arm, and the elastic band will be removed once the IV is inserted. After the elastic band is placed on the subject's arm, the arm will be cleaned, and then a small skin wheel will be created with the lidocaine that will be injected very close to where the IV will be placed. The IV will be placed within about a minute from the time when the lidocaine was injected.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Buzzy
Description: The Buzzy vibrating ice pack will be placed on the subject's arm with an elastic band around it, and it will remain there as the arm is cleaned and prepped and the IV inserted. The Buzzy device will be removed once the IV is inserted.
Study: NCT02627313

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GammaPod Tumour Bed Boost
Description: Single fraction Tumour Bed boost of 8Gy in 1 Fraction
Study: NCT06257654

Intervention type: DEVICE
Intervention: REZUM
Description: The 3rd and 12th month follow-ups of the patients who underwent REZUM operation were evaluated.
Study: NCT05736809

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-dye taping
Description: Low-dye taing using 4 tapes around calcaneam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plantar fascia stretching
Description: out of 21 participants 7 will be included in the study design as an active participants group using plantar fscia stretching in acute stage

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sham taping
Description: out of 21 participants 7 will be included in the study design as an plecebo group using sham taping in acute stage
Study: NCT05905809

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UniRelieverTM offloading brace (THUASNE)
Description: The patient will be instructed to wear the brace during walking and physical exercise. The investigator will explain to the patient how to adjust it

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Unloader One® X brace (Össur)
Description: The patient will be instructed to wear the brace during walking and physical exercise. The investigator will explain to the patient how to adjust it
Study: NCT05471063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphotericin B Colloidal Dispersion
Description: Amphotericin B Colloidal Dispersion 3.0-4.0 mg/kg/d (subject to adjustment, maximum dose not exceeding 6.0 mg/kg/d) . The course of induction therapy is at least four weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flucytosine
Description: Flucytosine 100 mg/kg/d for induction therapy and consolidation therapy of cryptococcal meningitis. The course of induction therapy is at least four weeks, and consolidation therapy for at least 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluconazole
Description: Fluconazole (400-600 mg/d) for consolidation therapy for at least 6 weeks.
Study: NCT06426186

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Right-stellate ganglion block
Description: The experimental group was given right stellate ganglion block 30 minutes before anesthesia
Study: NCT06351540

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cannabis
Description: cannabis with 0, 5, or 30 mg THC will be inhaled via vaporization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: cannabis with 0, 5, or 30 mg THC will be inhaled via vaporization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: cannabis with 0, 5, or 30 mg THC will be inhaled via vaporization
Study: NCT06219135

Intervention type: OTHER
Intervention: no intervention - Contamination group
Description: there is no intervention for this group of patients

Intervention type: BIOLOGICAL
Intervention: blood sample - Bacteraemia group
Description: for adult patients, in optional, blood sample will be taken. 27,5 ml of blood at H24-48 after inclusion and 5 ml of blood at day 30
Study: NCT04839133

Intervention type: DEVICE
Group type: OTHER
Intervention: MyoSuitFeasibility
Description: Participants will absolve feasibility tests with and without wearing a MyoSuit.
Study: NCT06172361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone+Tofacitinib
Description: Withdrawal of prednisone (or equivalent dose of methylprednisolone) within 4 weeks: 5mg tid for 2 weeks, 5mg bid for 1 week, 5mg qd for 1 week, then discontinue.~Take Tofacitinib 10mg/d for 3 months, then 7.5mg/d for 2 months, followed by 5mg qd for 2 months, then 5mg qod for 2 months, and finally 5mg every 3 days for 2 months, discontinue the Tofacitinib for 1 month. If there is a relapse during the dose reduction process, resume Tofacitinib at the original dosage.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone 15mg (or equivalent dose of methylprednisolone) was set as the initial treatment of PMR. When improvement was achieved, the dose of Prednisone was reduced to 10mg daily within 4-10 weeks; When remission was achieved, then taper Prednisone gradually by 2.5mg every 6-8 weeks. Once relapse occurred, the dose increased to the pre-relapse dose. If reducing pred dosage is difficult, Methotrexate (MTX) 10mg qw can be added after 24 weeks.
Study: NCT04657978

Intervention type: PROCEDURE
Intervention: Substrate guided left atrial ablation
Description: Ablation therapy targeting areas of low voltage, which may include encirclement, homogenization or targeting of abnormal electrograms and anchored to a non-conducting structure if the region is in close proximity or likely to create an isthmus for arrhythmias.
Study: NCT06516133

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity modulated radiation therapy (IMRT) with conventional planning target volume (PTV) margin and without online adaptive radiotherapy
Description: Radiation: Complete the full course of radiotherapy using the original treatment plan.~Planning target volume (PTV) margin: 3mm;

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Chemotherapy: If given, platinum-based.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiation therapy (IMRT) with smaller planning target volume (PTV) margin and online adaptive radiotherapy
Description: Radiation: During the course of radiotherapy, the treatment plan is adjusted online based on the anatomical and dosimetric changes in the target volumes and organs at risk of patients.~planning target volume (PTV) margin: smaller.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapy: If given, platinum-based
Study: NCT05031286

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cutaneous thermal stimuli
Description: Application of thermal stimuli of different intensities to the skin
Study: NCT05634616

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Motor imagery and motor execution based BCI
Description: We designed a motor imagery and motor execution-based BCI-controlled pedaling rehabilitation training system. Patients wore EEG caps and were instructed to imagine upper limb pedaling movements. The greater the patients' movement intention, the higher the Mscore of movement intention index on the monitor and the faster the pedaling speed

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham BCI
Description: The training equipment was the same, but the program was changed to record only the EEG signal without controlling the pedaling equipment, and the Mscore score and pedaling speed displayed by the equipment in real time were pre-set training performance data of the previous pretest patients, i.e., sham neurofeedback.
Study: NCT06105476

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Test drink with 12 g alcohol (30 g vodka 40%) in water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol+protein
Description: Test drink with 12 g alcohol (30 g vodka 40%) and 25 g whey protein in water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol+retinol
Description: Test drink with 12 g alcohol (30 g vodka 40%) and 1000 μg retinol in water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Retinol
Description: Test drink with 1000 μg retinol in water
Study: NCT06004817

Intervention type: OTHER
Intervention: evaluation of clinical severity
Description: evaluation of clinical severity

Intervention type: OTHER
Intervention: evaluation of clinical severity
Description: evaluation of clinical severity
Study: NCT05789875

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aDOT-CEI
Description: For the design and development of the mobile health app, we have partnered with AiCure to use an existing HIPAA-compliant mobile health app. The app will record video of the participant taking their HIV medication in order to monitor the participant's medication adherence and track incentives for this behavior in real-time.
Study: NCT06574334

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Proprioceptive exercise
Description: * The first session was included an orientation to the exercises and its purpose to geriatric participants in the first week. Also, pretest was done in the first session before implementing exercises to assess geriatric KOA pain and QOL, each session started by revision about what was given during the previous session and the objectives of the next session.~* The 2nd session about exercises.~* The 3rd session for repetition of exercises to ensure that the patient has learned it well in the second week.~* The 4th session after six weeks later (from wk. (3) to wk. (8) to make posttest after implementation session.~* The 5th session after two-month later (from wk. (9) to wk. (16) to do follow up test.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Proprioceptive exercise
Description: * The first session was included an orientation to the exercises and its purpose to geriatric participants in the first week. Also, pretest was done in the first session before implementing exercises to assess geriatric KOA pain and QOL, each session started by revision about what was given during the previous session and the objectives of the next session.~* The 2nd session about exercises.~* The 3rd session for repetition of exercises to ensure that the patient has learned it well in the second week.~* The 4th session after six weeks later (from wk. (3) to wk. (8) to make posttest after implementation session.~* The 5th session after two-month later (from wk. (9) to wk. (16) to do follow up test.
Study: NCT05268796

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavior therapy
Description: Caregivers will be coached either in-person or via telehealth to implement function-based behavioral treatment in 1-hour sessions each week with their child over 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavior therapy
Description: Caregivers will be coached either in-person or via telehealth to implement function-based behavioral treatment in 1-hour sessions each week with their child over 12 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Psychoeducation
Description: Caregivers will complete online education modules in 1-hour sessions each week over 12 weeks.
Study: NCT04419909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD19 redirected autologous T cells (CTL019 or CTL119 cells)
Description: Retreatment with CD19-directed Chimeric Antigen Receptor-modified T Cells (CART19 cells) or huCD19-directed Chimeric Antigen Receptor-modified T Cells (huCART19 cells) in subjects with late relapse of B-cell lymphomas.
Study: NCT06573333

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umblical Cord Clamping
Description: Umbilical Cord will be clamped using a plastic clamp at the noted time after delivery of the neonate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umblical Cord Clamping
Description: Umbilical Cord will be clamped using a plastic clamp at the noted time after delivery of the neonate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umblical Cord Clamping
Description: Umbilical Cord will be clamped using a plastic clamp at the noted time after delivery of the neonate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umblical Cord Clamping
Description: Umbilical Cord will be clamped using a plastic clamp at the noted time after delivery of the neonate
Study: NCT05206552

Intervention type: OTHER
Intervention: Questionnaire
Description: Maternal - Infant bonding questionnaire. EPDS - Postpartum depression questionnaire
Study: NCT06129656

Intervention type: OTHER
Intervention: Routine diagnostics
Description: Data collection of routine diagnostics

Intervention type: OTHER
Intervention: Routine treatment
Description: Data collection of routine treatment